Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells Songlin LiuYunhong TangYifeng Li PRECLINICAL STUDIES 06 March 2018 Pages: 961 - 969
The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivatives in human gastric cancer cells Natalia PawłowskaAgnieszka GornowiczKrzysztof Bielawski PRECLINICAL STUDIES Open access 17 March 2018 Pages: 970 - 984
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations Elisabetta BigagliCristina LuceriLorenzo Cinci PRECLINICAL STUDIES 02 April 2018 Pages: 985 - 998
Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation Atsushi OsoegawaTakafumi HashimotoKenji Sugio PRECLINICAL STUDIES 28 March 2018 Pages: 999 - 1005
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose Aurelia H. M. de Vries SchultinkRobert P. DoornbosAlwin D. R. Huitema PRECLINICAL STUDIES Open access 05 May 2018 Pages: 1006 - 1015
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors Carol AghajanianKatherine M. Bell-McGuinnJeffrey R. Infante PHASE I STUDIES 03 April 2018 Pages: 1016 - 1025
A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours Kyaw L. AungAnthony B. El-KhoueiryJayesh Desai PHASE I STUDIES 10 April 2018 Pages: 1026 - 1036
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer R. S. FinnD. H. AhnTanios S. Bekaii-Saab PHASE I STUDIES 22 May 2018 Pages: 1037 - 1043
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors Sandrine HiretNicolas IsambertJean-Pierre Delord PHASE I STUDIES 29 May 2018 Pages: 1044 - 1059
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors Michael CarducciMontaser ShaheenJayesh Desai PHASE I STUDIES 07 July 2018 Pages: 1060 - 1071
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients Won Young TakBaek-Yeol RyooMasatoshi Kudo PHASE II STUDIES 10 September 2018 Pages: 1072 - 1084
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study Pedro C. BarataMatthew CooneyJorge A. Garcia PHASE II STUDIES 06 September 2018 Pages: 1085 - 1092
Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases Naminatsu TakaharaYousuke NakaiKazuhiko Koike PHASE II STUDIES 15 October 2018 Pages: 1093 - 1102
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β Clinton YamRashmi K. MurthyBanu Arun PHASE II STUDIES 11 October 2018 Pages: 1103 - 1109
Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone Giandomenico RovielloRoberto PetrioliMichele Aieta PHASE II STUDIES 22 October 2018 Pages: 1110 - 1115
Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma Chongchong WangJuehua JingLi Cheng REVIEW 06 August 2018 Pages: 1116 - 1132
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer Navid SobhaniDaniele GeneraliGiandomenico Roviello REVIEW 07 August 2018 Pages: 1133 - 1137
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction Kei KunimasaTaiki IseiFumio Imamura SHORT REPORT 26 June 2018 Pages: 1138 - 1142
Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints Sarah E. StumpYoung E. WhangDaniel J. Crona SHORT REPORT 28 June 2018 Pages: 1143 - 1146
Design, synthesis and antiproliferative evaluation of novel sulfanilamide-1,2,3-triazole derivatives as tubulin polymerization inhibitors Shewei GuoYingwei ZhenGuosheng Zhou SHORT REPORT 18 July 2018 Pages: 1147 - 1157
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer Laura W. GoffNilofer S. AzadJordan D. Berlin Correction 18 October 2018 Pages: 1158 - 1158